Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Weekly News Recap #Phispers
US Medicaid
NA
Finished Drug Prices
NA
1. (1z)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentaazatetracyclo(13.5.2.04,9.018,22)docosa-1,4,6,8,15,19,21-heptaen-14-one
2. 1,15-etheno-1h-pyrazolo(4,3-f)(1,4,8,10)benzoxatriazacyclotridecin-4(5h)-one, 11-fluoro-2,6,7,13-tetrahydro-7,13-dimethyl-, (14z)-
1. Tpx-0005
2. 1802220-02-5
3. Ropotrectinib
4. 08o3fq4unp
5. Repotrectinib [usan]
6. Tpx0005
7. (3r,11s)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4(9),5,7,15(22),16,19-heptaen-14-one
8. Trx-0005
9. Repotrectinib (usan)
10. 1,15-etheno-1h-pyrazolo(4,3-f)(1,4,8,10)benzoxatriazacyclotridecin-4(5h)-one, 11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-, (7s,13r)-
11. Repotrectinib(tpx-005)
12. Unii-08o3fq4unp
13. Repotrectinib [inn]
14. Repotrectinib [who-dd]
15. Chembl4298138
16. Schembl16946804
17. Gtpl10316
18. Tpx 0005 [who-dd]
19. Bdbm374727
20. Ex-a2572
21. Tpx 0005
22. Us10246466, Example 93
23. Nsc800522
24. S8583
25. Akos037648789
26. Ccg-268096
27. Cs-7628
28. Nsc-800522
29. Ac-31283
30. Bs-15622
31. Example 93 [us20170334929a1]
32. Hy-103022
33. C73438
34. D11454
35. A910911
36. (13e,14e,3r,6s)-45-fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)-pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenacyclononaphan-9-one
37. (13e,14e,3r,6s)-45-fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)pyrazolo[1,5-a]pyrimidina-4(1,2)-benzenacyclononaphan-9-one
38. (1z)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentaazatetracyclo(13.5.2.04,9.018,22)docosa-1,4,6,8,15,19,21-heptaen-14-one
39. (3r,11s)-6-fluoro-3,11-dimethyl-10-oxa-2,13,17,18,21-pentaazatetracyclo[13.5.2.04,9.018,22]docosa-1(21),4,6,8,15(22),16,19-heptaen-14-one
40. (3r,6s,)-45-fluoro-3,6-dimethyl-5-oxa-2,8-diaza-1(5,3)-pyrazolo(1,5-a)pyrimidina-4(1,2)-benzenanonaphan-9-one
41. (7s,13r)-11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-1,15-etheno-1h-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5h)-one
42. (7s,13r)-11-fluoro-7,13-dimethyl-6,7,13,14- Tetrahydro-1,15-ethenopyrazolo[4,3- F][1,4,8,10]benzoxatriazacyclotridecin-4(5h)- One
43. 1,15-etheno-1h-pyrazolo(4,3-f)(1,4,8,10)benzoxatriazacyclotridecin-4(5h)-one, 11-fluoro-2,6,7,13-tetrahydro-7,13-dimethyl-, (14z)-
44. 1,15-etheno-1h-pyrazolo[4,3-f][1,4,8,10]benzoxatriazacyclotridecin-4(5h)-one,11-fluoro-6,7,13,14-tetrahydro-7,13-dimethyl-, (7s,13r)-
Molecular Weight | 355.4 g/mol |
---|---|
Molecular Formula | C18H18FN5O2 |
XLogP3 | 2.1 |
Hydrogen Bond Donor Count | 2 |
Hydrogen Bond Acceptor Count | 6 |
Rotatable Bond Count | 0 |
Exact Mass | 355.14445300 g/mol |
Monoisotopic Mass | 355.14445300 g/mol |
Topological Polar Surface Area | 80.6 Ų |
Heavy Atom Count | 26 |
Formal Charge | 0 |
Complexity | 524 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Global Sales Information
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Repotrectinib manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Repotrectinib, including repackagers and relabelers. The FDA regulates Repotrectinib manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Repotrectinib API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Repotrectinib manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Repotrectinib supplier is an individual or a company that provides Repotrectinib active pharmaceutical ingredient (API) or Repotrectinib finished formulations upon request. The Repotrectinib suppliers may include Repotrectinib API manufacturers, exporters, distributors and traders.
click here to find a list of Repotrectinib suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Repotrectinib as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Repotrectinib API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Repotrectinib as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Repotrectinib and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Repotrectinib NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Repotrectinib suppliers with NDC on PharmaCompass.
Repotrectinib Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Repotrectinib GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Repotrectinib GMP manufacturer or Repotrectinib GMP API supplier for your needs.
A Repotrectinib CoA (Certificate of Analysis) is a formal document that attests to Repotrectinib's compliance with Repotrectinib specifications and serves as a tool for batch-level quality control.
Repotrectinib CoA mostly includes findings from lab analyses of a specific batch. For each Repotrectinib CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Repotrectinib may be tested according to a variety of international standards, such as European Pharmacopoeia (Repotrectinib EP), Repotrectinib JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Repotrectinib USP).
LOOKING FOR A SUPPLIER?